Matthew Edward Hughes

Matthew Edward Hughes

Auto-generated profile, based on publicly available information

Matthew Edward Hughes

Centre for Mental Health, Swinburne University of Technology, Melbourne, VIC, Australia

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in Nature
Verified
Journal Article
Closed access
PDF file
RBRotem Botvinik-Nezer
Rotem Botvinik-Nezer
FHFelix Holzmeister
Felix Holzmeister
CCColin F. Camerer
Colin F. Camerer
ADAnna Dreber
Anna Dreber
JHJuergen Huber
Juergen Huber
TSTom Schonberg
Tom Schonberg

1 January 2012 in Biological Psychology
Verified
Journal Article
Closed access
MHMatthew Edward Hughes
Matthew Edward Hughes
WFWilliam Ross Fulham
William Ross Fulham
PJPat Johnston
Pat Johnston
PMPatricia Therese Michie
Patricia Therese Michie

17 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YJYuchao Jiang
Yuchao Jiang
Cheng LuoCheng Luo
Cheng Luo
JWJijun Wang
Jijun Wang
LENA PALANIYAPPANLENA PALANIYAPPAN
LENA PALANIYAPPAN
XCXiao Chang
Xiao Chang
ZCZIB Consortium
ZIB Consortium
Machine learning can be used to define subtypes of psychiatric conditions based on shared biological foundations of mental disorders. Here we analyzed cross-sectional brain images from 4,222 individuals with schizophrenia and 7038 healthy subjects pooled across 41 international cohorts from the ENIGMA, non-ENIGMA cohorts and public datasets. Using the Subtype and Stage Inference (SuStaIn) algorithm, we identify two distinct neurostructural subgroups by mapping the spatial and temporal ‘trajectory’ of gray matter change in schizophrenia. Subgroup 1 was characterized by an early cortical-predominant loss with enlarged striatum, whereas subgroup 2 displayed an early subcortical-predominant loss in the hippocampus, striatum and other subcortical regions. We confirmed the reproducibility of the two neurostructural subtypes across various sample sites, including Europe, North America and East Asia. This imaging-based taxonomy holds the potential to identify individuals with shared neurobiological attributes, thereby suggesting the viability of redefining existing disorder constructs based on biological factors.

16 February 2014 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
MHM. E. Hughes
M. E. Hughes
TBT. W. Budd
T. W. Budd
WFW. R. Fulham
W. R. Fulham
SLS. Lancaster
S. Lancaster
WWW. Woods
W. Woods
PMP. T. Michie
P. T. Michie

2 November 2015 in Trials
Verified
Journal Article
Open access
PDF file
KSKaren M. Savage
Karen M. Savage
CSCon Stough
Con Stough
GBGerard J. Byrne
Gerard J. Byrne
ASAndrew Scholey
Andrew Scholey
CBChad Bousman
Chad Bousman
JSJerome Sarris
Jerome Sarris
Generalised anxiety disorder (GAD) is a chronic and pervasive condition that generates high levels of psychological stress, and it is difficult to treat in the long term. Current pharmacotherapeutic options for GAD are in some cases only modestly effective, and may elicit undesirable side effects. Through targeted actions on the gamma-aminobutyric acid (GABA) pathway, the South Pacific medicinal plant kava (Piper methysticum) is a non-addictive, non-hypnotic anxiolytic with the potential to treat GAD. The evidence for the efficacy of kava for treating anxiety has been affirmed through clinical trials and meta-analyses. Recent research has also served to lessen safety concerns regarding the use of kava due to hepatotoxic risk, which is reflected in a recent German court overturning the previous kava ban in that country (which may in turn influence a reinstatement by the European Union). The aim of current research is to assess the efficacy of an ‘aqueous noble cultivar rootstock extract’ of kava in GAD in a larger longer term study. In addition, we plan to investigate the pharmacogenomic influence of GABA transporters on response, effects of kava on gene expression, and for the first time, the neurobiological correlates of treatment response via functional and metabolic imaging. This clinical trial is funded by the Australian National Health and Medical Research Council (APP1063383) and co-funded by MediHerb (Integria Healthcare (Australia) Pty. Ltd). The study is a phase III, multi-site, two-arm, 18-week, randomised, double-blind, placebo-controlled study using an aqueous extract of noble kava cultivar (standardised to 240 mg of kavalactones per day) versus matching placebo in 210 currently anxious participants with diagnosed GAD who are non-medicated. The study takes place at two sites: the Centre for Human Psychopharmacology (Swinburne University of Technology), Hawthorn, Melbourne, Australia; and the Academic Discipline of Psychiatry (The University of Queensland) based at the Royal Brisbane and Women’s Hospital, Herston, Brisbane, Australia. Written informed consent will be obtained from each participant prior to commencement in the study. The primary outcome is the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A). The secondary outcomes involve a range of scales that assess affective disorder symptoms and quality of life outcomes, in addition to the study of mediating biomarkers of response (assessed via genomics and neuroimaging). If this study demonstrates positive findings in support of the superiority of kava over placebo in the treatment of GAD, and also is shown to be safe, then this plant-medicine can be considered a ’first-line‘ therapy for GAD. Genomic and neuroimaging data may reveal clinical response patterns and provide more evidence of the neurobiological activity of the plant extract. ClinicalTrials.gov: NCT02219880 Date: 13 August 2014:

1 November 2013 in Behavioural Brain Research
Verified
Journal Article
Closed access
MHMatthew Edward Hughes
Matthew Edward Hughes
PJPat Johnston
Pat Johnston
WFWilliam Ross Fulham
William Ross Fulham
TBTimothy William Budd
Timothy William Budd
PMPatricia Therese Michie
Patricia Therese Michie